SCHEMBL10106392

SCHEMBL10106392

CNc1ccnc2ccc(S(=O)(=O)C(C)(C)C)cc12

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 14/20 0.67
KCNH2 Q12809 8/20 0.67
MAPK14 Q16539 2/20 0.57
GAK O14976 2/20 0.57
RIPK3 Q9Y572 2/20 0.57
LCK P06239 1/20 0.57
TGFBR1 P36897 1/20 0.57
KDR P35968 2/20 0.46
RET P07949 1/20 0.46
PKMYT1 Q99640 1/20 0.46
SLC22A12 Q96S37 2/20 0.46
RIPK1 Q13546 2/20 0.42
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HTR1A P08908 1/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40
ADRA1B P35368 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10119049 0.82 RIPK2 (0.57) RIPK2KCNH2MAPK14GAKRIPK3
SCHEMBL23999580 0.82 CA9 (0.54) RIPK2KCNH2MAPK14GAKRIPK3
SCHEMBL600081 0.81 RIPK2 (0.58) RIPK2KCNH2MAPK14GAKRIPK3
SCHEMBL600768 0.80 RIPK2 (0.60) RIPK2KCNH2MAPK14GAKRIPK3
SCHEMBL601819 0.78 RIPK2 (1.00) RIPK2KCNH2MAPK14GAKRIPK3
SCHEMBL17059454 0.78 RIPK2 (0.54) RIPK2KCNH2MAPK14GAKRIPK3
SCHEMBL18670892 0.78 RIPK2 (0.50) RIPK2KCNH2MAPK14GAKRIPK3
Water SCHEMBL601248 0.78 RIPK2 (0.98) RIPK2KCNH2MAPK14GAKRIPK3
SCHEMBL18670894 0.77 RIPK2 (0.47) RIPK2KCNH2MAPK14GAKRIPK3
SCHEMBL18670901 0.77 RIPK2 (0.47) RIPK2KCNH2MAPK14GAKRIPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041024-A1 QUINOLYL AMINES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2012-02-16 US disclosed
US-20120041024-A1 QUINOLYL AMINES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041024-A1 QUINOLYL AMINES AS KINASE INHIBITORS ABL1, MAP3K20, MAP3K19 RIPK2 480/4885KCNH2 824/4885MAPK14 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.